Momenta Pharmaceuticals Announces Positive Results |
![]() |
![]() |
By Staff and Wire Reports |
Thursday, 24 September 2009 14:17 |
![]() "M118, our first novel product engineered utilizing Momenta technology, was rationally designed to capture the positive attributes of both unfractionated heparin and low molecular weight heparin," commented Jim Roach, M.D., Chief Medical Officer at Momenta. "We are very pleased with the results from the EMINENCE trial, which support our belief that M118 has the potential to become the baseline anticoagulant of choice for treatment of patients diagnosed with acute coronary syndromes." The primary objective of EMINENCE was to evaluate the safety and feasibility of utilizing M118 as an anticoagulant in the target population of patients with stable coronary artery disease (CAD) undergoing a percutaneous coronary intervention (PCI). Approximately 500 patients with stable CAD undergoing elective PCI were randomly assigned to receive treatment with one of three doses of intravenous M118 or a standard dose of unfractionated heparin (UFH). The primary endpoint of the study was the combined incidence of clinical events defined as the composite of death, myocardial infarction (MI), repeat revascularization, and stroke (over thirty days); incidence of bleeding and thrombocytopenia (over the first 24 hours); and bailout use of glycoprotein IIb/IIIa inhibitors and catheter thrombus (during the procedure). Safety was also evaluated by assessing the incidence of adverse events and serious adverse events. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |